Mouse models for mesothelioma drug discovery and development

References

• Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the mesothelioma avastin cisplatin pemetrexed study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016 Apr 02;387(10026):1405–1414.
   PubMed Web of Science ®Google Scholar
• Mazurek JM, Syamlal G, Wood JM, et al. Malignant mesothelioma mortality — United States, 1999–2015. MMWR Morb Mortal Wkly Rep. 2017;66(8):214–218.
   PubMed Web of Science ®Google Scholar
• Stayner L, Welch LS, Lemen R. The worldwide pandemic of asbestos-related diseases. Annu Rev Public Health. 2013;34:205–216.
   PubMed Web of Science ®Google Scholar
• Liu B, Van Gerwen M, Bonassi S, et al. Epidemiology of environmental exposure and malignant mesothelioma. J Thorac Oncol. 2017;12(7):1031–1045.
   PubMed Web of Science ®Google Scholar
• Galateau-Salle F, Churg A, Roggli V, et al., World Health Organization Committee for Tumors of the P. The 2015 World Health Organization classification of tumors of the pleura: advances since the 2004 classification. J Thorac Oncol. 2016 Feb;11(2):142–154.
   PubMed Web of Science ®Google Scholar
• Mansfield AS, Peikert T, Vasmatzis G. Chromosomal rearrangements and their neoantigenic potential in mesothelioma. Transl Lung Cancer Res. 2020 Feb;9(Suppl 1):S92–S99.
   PubMed Web of Science ®Google Scholar
• Bueno R, Stawiski EW, Goldstein LD, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016 Apr;48(4):407–416.
   PubMed Web of Science ®Google Scholar
• Yap TA, Aerts JG, Popat S, et al. Novel insights into mesothelioma biology and implications for therapy. Nat Rev Cancer. 2017 Jul 25;17(8):475–488.
   PubMed Web of Science ®Google Scholar
• Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003 Jul 15;21(14):2636–2644.
   PubMed Web of Science ®Google Scholar
• Network NCC. Malignant pleural mesothelioma (Version1.2020). 2020 [cited 2020 May 21]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/mpm.pdf
   Google Scholar
• Scherpereel A, Opitz I, Berghmans T, et al. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur Respir J. 2020;55(6):1900953.
   PubMed Web of Science ®Google Scholar
• Belderbos RA, Baas P, Berardi R, et al. A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: dENdritic cell Immunotherapy for Mesothelioma (DENIM) trial. Transl Lung Cancer Res. 2019 Jun;8(3):280–285.
   PubMed Web of Science ®Google Scholar
• Zauderer MG, Tsao AS, Dao T, et al. A randomized phase ii trial of adjuvant Galinpepimut-S, WT-1 Analogue Peptide vaccine, after multimodality therapy for patients with malignant pleural mesothelioma. Clin Cancer Res. 2017;23(24):7483–7489.
   PubMed Web of Science ®Google Scholar
• Hassan R, Miller AC, Sharon E, et al. Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. Sci Transl Med. 2013 Oct 23;5(208):208ra147.
   PubMed Web of Science ®Google Scholar
• Hassan R, Alley E, Kindler H, et al. Clinical response of live-attenuated, listeria monocytogenes expressing mesothelin (CRS-207) with chemotherapy in patients with malignant pleural mesothelioma. Clin Cancer Res. 2019;25(19):5787–5798.
   PubMed Web of Science ®Google Scholar
• Kiesgen S, Chicaybam L, Chintala NK, et al. Chimeric antigen receptor (CAR) T-cell therapy for thoracic malignancies. J Thorac Oncol. 2018;13(1):16–26.
   PubMed Web of Science ®Google Scholar
• Szlosarek PW, Steele JP, Nolan L, et al. Arginine deprivation with pegylated arginine deiminase in patients with argininosuccinate synthetase 1-deficient malignant pleural mesothelioma: a randomized clinical trial. JAMA Oncol. 2017 Jan 1;3(1):58–66.
   PubMed Web of Science ®Google Scholar
• Singh A, Pruett N, Hoang CD. In vitro experimental models of mesothelioma revisited. Transl Lung Cancer Res. 2017 6;Jun(3):248–258.
   Google Scholar
• Miselis NR, Wu ZJ, Van Rooijen N, et al. Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma. Mol Cancer Ther. 2008 Apr;7(4):788–799.
   PubMed Web of Science ®Google Scholar
• Spugnini EP, Cardillo I, Verdina A, et al. Piroxicam and cisplatin in a mouse model of peritoneal mesothelioma. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6133–6143.
   PubMed Web of Science ®Google Scholar
• Blanquart C, Jaurand M-C, Jean D. The biology of malignant mesothelioma and the relevance of preclinical models. Front Oncol. 2020;10. DOI:10.3389/fonc.2020.00388
   PubMed Web of Science ®Google Scholar
• Jean D, Jaurand M-C. Mesotheliomas in genetically engineered mice unravel mechanism of mesothelial carcinogenesis. Int J Mol Sci. 2018;19(8):2191.
   Web of Science ®Google Scholar
• Testa JR, Berns A. Preclinical models of malignant mesothelioma. Front Oncol. 2020;10. DOI:10.3389/fonc.2020.00101
   PubMed Web of Science ®Google Scholar
• Bozelka BE, Sestini P, Gaumer HR, et al. A murine model of asbestosis. Am J Pathol. 1983 Sep;112(3):326–337.
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Kohyama N. Malignant mesothelioma induced by asbestos and zeolite in the mouse peritoneal cavity. Environ Res. 1984 Oct;35(1):277–292.
   PubMed Web of Science ®Google Scholar
• Dragon J, Thompson J, MacPherson M, et al. Differential susceptibility of human pleural and peritoneal mesothelial cells to asbestos exposure. J Cell Biochem. 2015 Aug;116(8):1540–1552.
   PubMed Web of Science ®Google Scholar
• Marsella JM, Liu BL, Vaslet CA, et al. Susceptibility of p53-deficient mice to induction of mesothelioma by crocidolite asbestos fibers. Environ Health Perspect. 1997;105(suppl 5):1069–1072.
   PubMed Web of Science ®Google Scholar
• Fleury-Feith J, Lecomte C, Renier A, et al. Hemizygosity of Nf2 is associated with increased susceptibility to asbestos-induced peritoneal tumours. Oncogene. 2003 Jun 12;22(24):3799–3805.
   PubMed Web of Science ®Google Scholar
• Altomare DA, Vaslet CA, Skele KL, et al. A mouse model recapitulating molecular features of human mesothelioma. Cancer Res. 2005 Sep 15;65(18):8090–8095.
   PubMed Web of Science ®Google Scholar
• Altomare DA, Menges CW, Xu J, et al. Losses of both products of the Cdkn2a/Arf locus contribute to asbestos-induced mesothelioma development and cooperate to accelerate tumorigenesis. PLoS One. 2011 Apr 19;6(4):e18828.
   PubMed Web of Science ®Google Scholar
• Menges CW, Kadariya Y, Altomare D, et al. Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis. Cancer Res. 2014 Feb 15;74(4):1261–1271.
   PubMed Web of Science ®Google Scholar
• Kadariya Y, Menges CW, Talarchek J, et al. Inflammation-related IL1β/IL1R signaling promotes the development of asbestos-induced malignant mesothelioma. Cancer Prev Res (Phila). 2016 May;9(5):406–414.
   PubMed Web of Science ®Google Scholar
• Napolitano A, Pellegrini L, Dey A, et al. Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma. Oncogene. 2016 Apr 14;35(15):1996–2002.
   PubMed Web of Science ®Google Scholar
• Robinson C, van Bruggen I, Segal A, et al. A novel SV40 TAg transgenic model of asbestos-induced mesothelioma: malignant transformation is dose dependent. Cancer Res. 2006 Nov 15;66(22):10786–10794.
   PubMed Web of Science ®Google Scholar
• López-Ríos F, Illei PB, Rusch V, et al. Evidence against a role for SV40 infection in human mesotheliomas and high risk of false-positive PCR results owing to presence of SV40 sequences in common laboratory plasmids. Lancet. 2004;364(9440):1157–1166.
   PubMed Web of Science ®Google Scholar
• Jongsma J, van Montfort E, Vooijs M, et al. A conditional mouse model for malignant mesothelioma. Cancer Cell. 2008 Mar;13(3):261–271.
   PubMed Web of Science ®Google Scholar
• Kukuyan AM, Sementino E, Kadariya Y, et al. Inactivation of Bap1 cooperates with losses of Nf2 and Cdkn2a to drive the development of pleural malignant mesothelioma in conditional mouse models. Cancer Res. 2019 Aug 15;79(16):4113–4123.
   PubMed Web of Science ®Google Scholar
• Badhai J, Pandey GK, Song JY, et al. Combined deletion of Bap1, Nf2, and Cdkn2ab causes rapid onset of malignant mesothelioma in mice. J Exp Med. 2020 Jun 1;217(6). DOI:10.1084/jem.20191257.
   PubMed Web of Science ®Google Scholar
• Marqués M, Tranchant R, Risa-Ebrí B, et al. Combined MEK and PI3K/p110β Inhibition as a novel targeted therapy for malignant mesothelioma displaying sarcomatoid features. Cancer Res. 2020;80(4):843–856.
   PubMed Web of Science ®Google Scholar
• Chernova T, Sun XM, Powley IR, et al. Molecular profiling reveals primary mesothelioma cell lines recapitulate human disease. Cell Death Differ. 2016;23(7):1152–1164.
   PubMed Web of Science ®Google Scholar
• Szymiczek A, Pastorino S, Larson D, et al. FTY720 inhibits mesothelioma growth in vitro and in a syngeneic mouse model. J Transl Med. 2017 Mar 15;15(1):58.
   PubMedGoogle Scholar
• Moon EK, Carpenito C, Sun J, et al. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res. 2011 Jul 15;17(14):4719–4730.
   PubMed Web of Science ®Google Scholar
• Merritt RE, Yamada RE, Wasif N, et al. Effect of inhibition of multiple steps of angiogenesis in syngeneic murine pleural mesothelioma. Ann Thorac Surg. 2004 Sep;78(3):1042–1051. discussion 42-51
   PubMed Web of Science ®Google Scholar
• Adusumilli PS, Cherkassky L, Villena-Vargas J, et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med. 2014 Nov 5;6(261):261ra151.
   PubMed Web of Science ®Google Scholar
• Choi Y, Lee S, Kim K, et al. Studying cancer immunotherapy using patient-derived xenografts (PDXs) in humanized mice. Exp Mol Med. 2018;50:8.
   PubMed Web of Science ®Google Scholar
• Wu L, Allo G, John T, et al. Patient-derived xenograft establishment from human malignant pleural mesothelioma. Clin Cancer Res. 2017 Feb 15;23(4):1060–1067.
   PubMed Web of Science ®Google Scholar
• Abu Lila AS, Kato C, Fukushima M, et al. Downregulation of thymidylate synthase by RNAi molecules enhances the antitumor effect of pemetrexed in an orthotopic malignant mesothelioma xenograft mouse model. Int J Oncol. 2016;48(4):1399–1407.
   PubMed Web of Science ®Google Scholar
• Bertino P, Premeaux TA, Fujita T, et al. Targeting the C-terminus of galectin-9 induces mesothelioma apoptosis and M2 macrophage depletion. OncoImmunology. 2019;8(8):1601482.
   PubMed Web of Science ®Google Scholar
• Abayasiriwardana KS, Wood MK, Prêle CM, et al. Inhibition of collagen production delays malignant mesothelioma tumor growth in a murine model. Biochem Biophys Res Commun. 2019;510(2):198–204.
   PubMed Web of Science ®Google Scholar
• Benvenuto M, Mattera R, Sticca JI, et al. Effect of the BH3 Mimetic Polyphenol (-)-Gossypol (AT-101) on the in vitro and in vivo growth of malignant mesothelioma. Front Pharmacol. 2018;9:9.
   PubMed Web of Science ®Google Scholar
• Szymiczek A, Carbone M, Pastorino S, et al. Inhibition of the spindle assembly checkpoint kinase Mps-1 as a novel therapeutic strategy in malignant mesothelioma. Oncogene. 2017;36(46):6501–6507.
   PubMed Web of Science ®Google Scholar
• Szymiczek A, Pastorino S, Larson D, et al. FTY720 inhibits mesothelioma growth in vitro and in a syngeneic mouse model. J Transl Med. 2017;15:1.
   PubMed Web of Science ®Google Scholar
• Lam SK, Yan S, Xu S, et al. Targeting polyamine as a novel therapy in xenograft models of malignant pleural mesothelioma. Lung Cancer. 2020 Oct;148:138–148.
   PubMed Web of Science ®Google Scholar
• Peerschke E, Stier K, Li X, et al. gC1qR/HABP1/p32 is a potential new therapeutic target against mesothelioma. Front Oncol. 2020;10. DOI:10.3389/fonc.2020.01413
   PubMed Web of Science ®Google Scholar
• Cho H, Matsumoto S, Fujita Y, et al. Trametinib plus 4-methylumbelliferone exhibits antitumor effects by ERK blockade and CD44 downregulation and affects PD-1 and PD-L1 in malignant pleural mesothelioma. J Thorac Oncol. 2017;12(3):477–490.
   PubMed Web of Science ®Google Scholar
• Meerang M, Kreienbühl J, Orlowski V, et al. Importance of Cullin4 Ubiquitin ligase in malignant pleural mesothelioma. Cancers (Basel). 2020;12(11):3460.
   Web of Science ®Google Scholar
• Di Meo F, Filosa S, Madonna M, et al. Curcumin C3 complex®/Bioperine® has antineoplastic activity in mesothelioma: an in vitro and in vivo analysis. J Exp Clin Cancer Res. 2019;38(1). DOI:10.1186/s13046-019-1368-8.
   PubMed Web of Science ®Google Scholar
• Hayashi M, Yamada N, Morimoto S, et al. Novel antibody-drug conjugate with Anti-CD26 humanized monoclonal antibody and transcription factor IIH (TFIIH) inhibitor, triptolide, inhibits tumor growth via impairing mRNA synthesis. Cancers (Basel). 2019;11(8):1138.
   PubMed Web of Science ®Google Scholar
• Singh A, Bhattacharyya N, Srivastava A, et al. MicroRNA-215-5p treatment suppresses mesothelioma progression via the MDM2-p53-signaling axis. Mol Ther. 2019;27(9):1665–1680.
   PubMed Web of Science ®Google Scholar
• Sato A, Arai T, Fusegi M, et al. Derivative of tocotrienol suppresses tumor growth of mesothelioma cells in a xenograft model. Biol Pharm Bull. 2019;42(6):1034–1037.
   PubMed Web of Science ®Google Scholar
• Villanova T, Gesmundo I, Audrito V, et al. Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma. Proceedings of the National Academy of Sciences. 2019;116 (6):2226–2231.
   Google Scholar
• Laszlo V, Valko Z, Kovacs I, et al. Nintedanib is active in malignant pleural mesothelioma cell models and inhibits angiogenesis and tumor growth in vivo. Clin Cancer Res. 2018;24(15):3729–3740.
   PubMed Web of Science ®Google Scholar
• Ohara Y, Chew SH, Misawa N, et al. Connective tissue growth factor-specific monoclonal antibody inhibits growth of malignant mesothelioma in an orthotopic mouse model. Oncotarget. 2018 Apr 6;9(26):18494–18509.
   PubMedGoogle Scholar
• Otsuki T, Nakashima T, Hamada H, et al. Aminopeptidase N/CD13 as a potential therapeutic target in malignant pleural mesothelioma. Eur Respir J. 2018;51(5):1701610.
   PubMed Web of Science ®Google Scholar
• Tatsuta T, Satoh T, Sugawara S, et al. Sialic acid-binding lectin from bullfrog eggs inhibits human malignant mesothelioma cell growth in vitro and in vivo. Plos One. 2018;13(1):e0190653.
   PubMed Web of Science ®Google Scholar
• Urso L, Cavallari I, Silic-Benussi M, et al. Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists. Oncotarget. 2017;8(27):44232–44241.
   PubMedGoogle Scholar
• Tiberio P, Cavadini E, Cleris L, et al. Sodium 4-Carboxymethoxyimino-(4-HPR) a novel water-soluble derivative of 4-Oxo-4-HPR endowed with in vivo anticancer activity on solid tumors. Front Pharmacol. 2017;8:8.
   PubMed Web of Science ®Google Scholar
• Pellegrini L, Xue J, Larson D, et al. HMGB1 targeting by ethyl pyruvate suppresses malignant phenotype of human mesothelioma. Oncotarget. 2017;8(14):22649–22661.
   PubMedGoogle Scholar
• Zhang J, Khanna S, Jiang Q, et al. Efficacy of anti-mesothelin immunotoxin RG7787 plus nab-paclitaxel against mesothelioma patient–derived xenografts and mesothelin as a biomarker of tumor response. Clin Cancer Res. 2017;23(6):1564–1574.
   PubMed Web of Science ®Google Scholar
• Lam S-K, Li -Y-Y, Xu S, et al. Growth suppressive effect of pegylated arginase in malignant pleural mesothelioma xenografts. Respir Res. 2017;18:1.
   PubMed Web of Science ®Google Scholar
• Lee J-H, Kim H, Yao Z, et al. Tumor-Shed Antigen Affects Antibody Tumor Targeting: comparison of Two 89Zr-Labeled Antibodies Directed against Shed or Nonshed Antigens. Contrast Media Mol Imaging. 2018;2018:1–12.
   Google Scholar
• Xu Y, Yang B, Gao L, et al. Endoplasmic reticulum stress signaling as a therapeutic target in malignant pleural mesothelioma. Cancers (Basel). 2019;11(10):1502.
   Web of Science ®Google Scholar
• Vázquez R, Licandro SA, Astorgues-Xerri L, et al. Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK-8628 in malignant pleural mesothelioma xenografts. Int J Cancer. 2017;140(1):197–207.
   PubMed Web of Science ®Google Scholar
• Shapiro IM, Kolev VN, Vidal CM, et al. Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship. Sci Transl Med. 2014;6(237):237ra68–37ra68.
   PubMed Web of Science ®Google Scholar
• Hoffmann PR, Hoffmann FW, Premeaux TA, et al. Multi-antigen vaccination with simultaneous engagement of the OX40 receptor delays malignant mesothelioma growth and increases survival in animal models. Front Oncol. 2019;9:9.
   PubMed Web of Science ®Google Scholar
• Dammeijer F, Lievense LA, Kaijen-Lambers ME, et al. Depletion of tumor-associated macrophages with a CSF-1R kinase inhibitor enhances antitumor immunity and survival induced by DC immunotherapy. Cancer Immunol Res. 2017;5(7):535–546.
   PubMed Web of Science ®Google Scholar
• Otsuka K, Mitsuhashi A, Goto H, et al. Anti-PD-1 antibody combined with chemotherapy suppresses the growth of mesothelioma by reducing myeloid-derived suppressor cells. Lung Cancer. 2020 Aug;146:86–96.
   PubMed Web of Science ®Google Scholar
• Covre A, Coral S, Nicolay H, et al. Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models. OncoImmunology. 2015;4(8):e1019978.
   PubMed Web of Science ®Google Scholar
• Sandhu H. mRNA expression patterns in different stages of asbestos-induced carcinogenesis in rats. Carcinogenesis. 2000;21(5):1023–1029.
   PubMed Web of Science ®Google Scholar
• Hodge RD, Bakken TE, Miller JA, et al. Conserved cell types with divergent features in human versus mouse cortex. Nature. 2019 Sep;573(7772):61–68.
   PubMed Web of Science ®Google Scholar
• Fischer M. Mice are not humans: the case of p53. Trends Cancer. 2020. DOI:10.1016/j.trecan.2020.08.007
   Web of Science ®Google Scholar
• Xu D, Nishimura T, Nishimura S, et al. Fialuridine induces acute liver failure in chimeric TK-NOG mice: a model for detecting hepatic drug toxicity prior to human testing. PLoS Med. 2014 Apr;11(4):e1001628.
   PubMed Web of Science ®Google Scholar
• Hensel JA, Khattar V, Ashton R, et al. Characterization of immune cell subtypes in three commonly used mouse strains reveals gender and strain-specific variations. Lab Invest. 2019;99(1):93–106.
   PubMed Web of Science ®Google Scholar
• Petkova SB, Yuan R, Tsaih SW, et al. Genetic influence on immune phenotype revealed strain-specific variations in peripheral blood lineages. Physiol Genomics. 2008;34(3):304–314.
   PubMed Web of Science ®Google Scholar
• Dostert C, Petrilli V, Van Bruggen R, et al. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science. 2008 May 2;320(5876):674–677.
   PubMed Web of Science ®Google Scholar
• Lee H, Yoon DE, Kim K. Genome editing methods in animal models. Anim Cells Syst (Seoul). 2020;24(1):8–16.
   PubMed Web of Science ®Google Scholar
• Carbone M, Yang H. Mesothelioma: recent highlights. Ann Transl Med. 2017 Jun;5(11):238.
   PubMed Web of Science ®Google Scholar
• Hillegass JM, Shukla A, Lathrop SA, et al. Inflammation precedes the development of human malignant mesotheliomas in a SCID mouse xenograft model. Ann N Y Acad Sci. 2010 Aug;1203:7–14.
   PubMed Web of Science ®Google Scholar
• Bera TK, Pastan I. Mesothelin is not required for normal mouse development or reproduction. Mol Cell Biol. 2000 Apr;20(8):2902–2906.
   PubMed Web of Science ®Google Scholar
• Herndler-Brandstetter D, Shan L, Yao Y, et al. Humanized mouse model supports development, function, and tissue residency of human natural killer cells. Proc Natl Acad Sci U S A. 2017 Nov 7;114(45):E9626–e34.
   PubMed Web of Science ®Google Scholar